Table 1.
Baseline characteristics.
| Characteristics | Total (N=70) |
|---|---|
| Sex, male (N, %) | 34 |
| Age at study enrollment, years (median, range) | 69 (24-90) |
| >60 years old | 50 (71.4) |
| Diagnosis to study enrollment, days (median, range) | 13 (0-792) |
| Mutation status (N, %) | |
| JAK2V617F | 48/69 (68.6) |
| CALR | 6/69 (8.6) |
| MPL | 6/69 (8.6) |
| Triple negative | 13/69 (18.8) |
| Previous drug exposure (N, %) | |
| Hydroxyurea | 0 (0) |
| Anagrelide | 0 (0) |
| Interferon | 0 (0) |
| Baseline laboratory findings (mean, ± SD) | |
| WBC (x109/L) | 10.4 (0.4) |
| Hemoglobin (g/dL) | 13.8 (0.2) |
| Platelet (x109/L) | 931.4 (40.0) |
| Baseline platelet > 1000 x 109/L | 21 (30.0) |
| Cardiovascular risk factors (N, %) | |
| Hypertension | 29 (41.4) |
| Diabetes | 11 (15.7) |
| Dyslipidemia | 10 (14.3) |
| BMI > 25 | 27 (38.6) |
| Prior history of thrombosis | 13 (18.6) |
| IPSET-Thrombosis risk stratification | |
| Low | 7 (10.0) |
| Intermediate | 6 (8.6) |
| High | 57 (81.4) |
ET, essential thrombocythemia; SD, standard deviation; WBC, white blood cell count; BMI, body mass index; IPSET, International Prognostic Score.